---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003156"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:57:42.073767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront

## Summary
- Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.
- Phase 2 B-SUPREME interim analysis: DSMB recommended increasing HBeAg- sample size to 100; futility criteria not met.
- Exclusive license with Amoytop for Greater China: $25M upfront, up to $420M milestones plus tiered royalties.
- Cash, equivalents, investments $54.9M at March 31, 2026 (Dec 31, 2025: $77.8M); expected to fund into Q4 2026 inclusive of $25M upfront.
- Net loss Q1 2026: $23.0M ($2.21/share) vs net income $43.1M ($5.12/share) in Q1 2025.

## SEC filing metadata
- accession: 0001171843-26-003156
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/0001171843-26-003156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/f8k_050726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003156
- JSON: https://secwatch.observer/filing/0001171843-26-003156.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003156.txt

## Source-grounded claims
- claim_id: 20210700f35b7481245378a29b7d4b86689df05b
  claim: Aligos Therapeutics, Inc. reported first quarter 2026 results: net income Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $, EPS $(2.21).
  evidence_excerpt: Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $(2.21)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/0001171843-26-003156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.